Table 1.
Patients characteristics
| Characteristics | Total n = 134 |
TD(+) n = 40 |
TD(−) n = 94 |
p value (TD(+) vs TD(−) |
|---|---|---|---|---|
| Patients | ||||
| Age | ||||
| Mean ± SD | 62.5 ± 8.9 | 63.2 ± 9.2 | 62.2 ± 8.8 | 0.561 |
| ≥ 70 years old (%) | 26 (19.4) | 8 (20) | 18 (19.1) | 0.909 |
| Sex. male (%) | 94 (70.1) | 27 (67.5) | 67 (71.3) | 0.662 |
| Smoking (n = 131) (%) | ||||
| Current or former smoker | 128 (97.7) | 39 (100) | 89 (96.7) | 0.254 |
| WHO Performance Score (n = 119) (%) | ||||
| 0–1 | 92 (77.3) | 33 (86.8) | 59 (72.8) | 0.089 |
| ≥ 2 | 27 (22.7) | 5 (13.2) | 22 (27.2) | |
| Tumor | ||||
| Pathologic subtypes (%) | ||||
| Squamous cells carcinoma | 35 (26.1) | 16 (40) | 19 (20.2) | |
| Non-squamous cells carcinoma | 96 (71.6) | 23 (57.5) | 73 (77.7) | 0.055 |
| Undifferentiated | 3 (2.2) | 1 (2.5) | 2 (2.1) | |
| Stage (%) | ||||
| IIIB | 9 (6.7) | 6 (15) | 3 (3.2) | 0.012 |
| IV | 125 (93.3) | 34 (85) | 91 (96.8) | |
| Brain metastasis (%) | 39 (29.1) | 12 (30) | 27 (28.7) | 0.882 |
| Tumoral PD-L1 expression (n = 44) (%) | ||||
| ≤ 5% | 34 (77.3) | 11 (73.3) | 23 (79.3) | 0.654 |
| > 5% | 10 (22.7) | 4 (26.7) | 6 (20.7) | |
| Past regimens | ||||
| Number of regimens (%) | ||||
| 1 | 101 (75.4) | 33 (82.5) | 68 (72.3) | |
| 2 | 26 (19.4) | 5 (12.5) | 21 (22.3) | 0.409 |
| ≥ 3 | 7 (5.2) | 2 (5) | 5 (5.3) | |
| Radiotherapy (%) | 69 (51.5) | 20 (50) | 49 (52.1) | 0.822 |
| Other ICI (%) | 4 (3) | 1 (2.5) | 3 (3.2) | 0.830 |
| Best therapeutic response (n = 120) (%) | ||||
| Partial or complete response (%) | 27 (22.5) | 6 (16.2) | 21 (25.3) | |
| Stable disease | 45 (37.5) | 15 (40.5) | 30 (36.1) | 0.546 |
| Progression | 48 (40) | 16 (43.2) | 32 (38.6) | |
| Biology | ||||
| LIPI score (dNLR > 3 et LDH > ULN) (n = 93) (%) | ||||
| 0: good | 26 (28) | 14 (41.2) | 12 (20.3) | |
| 1: intermediate | 38 (40.9) | 14 (41.2) | 24 (40.7) | 0.039 |
| 2: poor | 29 (31.2) | 6 (17.6) | 23 (39) | |
|
Pre-Nivolumab TSH level(mIU/L) Mean ± SD |
1.70 ± 0.98 | 1.90 ± 1.06 | 1.61 ± 0.94 | 0.126 |
dNLR; derived neutrophil/leukocyte-lymphocyte ratio; ICI: immune checkpoint inhibitors; LIPI: lung immune prognostic index; PD-L1: programmed cell death ligand 1; TD(+): thyroid dysfunction (+) group